Vendor Intelligence Report: Xingruida XDR

Published 3 Jul 2026. 29-page investigative report on who is behind Xingruida XDR: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Across 73 Finnrick lab tests, Xingruida XDR shows a 68% pass rate: Retatrutide and Tirzepatide look comparatively stronger, while Tesamorelin is the clearest weak spot and the middle of the catalog…